logo
  • Über uns
    • Über uns
    • Führungsteam
    • Partnerschaften
    • Unsere Standorte
  • Technologie
    • Technologie
    • Produktion
    • Publikationen
  • Pipeline
  • Newsroom
    • News
    • Events
    • Downloads
  • Investor Relations
    • Überblick
    • Aktieninformation
    • Analysten-Coverage
    • Außerordentliche Hauptversammlung 2023
    • Finanzberichte
    • Corporate Governance
    • E-Mail Alert
  • Karriere
    • Werden Sie Teil der RNA people
    • Ausbildung
    • Aktuelle Stellenangebote
  • DE

Prophylactic Vaccines

Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine


by Bettina Joedicke-Braas

mRNA-Based Vaccines and Mode of Action


by Bettina Joedicke-Braas

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial


by Sovereign

New Vaccine Technologies to Combat Outbreak Situations


by Sovereign

Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors


by Sovereign

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines


by Sovereign

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial


by Sovereign

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response


by Sovereign

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity


by Sovereign

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs


by Sovereign

  • 1
  • 2